CA-BOEHRINGER-INGELHEIM
9.1.2023 17:01:41 CET | Business Wire | Press release
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds, further strengthening the company’s pipeline.
Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T‘s platform aims to address this challenge by identifying novel shared T-cell receptor (TCR) targets of productive immune responses and comprehensively screening TCRs and TCR mimetics for specificity and off-target cross-reactivities. The platform identifies the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning. This may lead to tumor-specific, safer therapies that can be delivered at higher doses.
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.
“On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.”
Under the agreement, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T’s target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones totaling $268 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
For the full press release and link to “Notes to Editors” please click here:
Press Release
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005420/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Orifarm Unveils 2031 Strategy to Accelerate Growth Across Europe, With Significant Expansion in Generics1.10.2026 08:10:00 CEST | Press release
With its five-year strategy, Fit to Scale, Orifarm sets out an ambitious path to scale across Europe, including a major expansion of its prescription medicines business from a Nordic footprint to a broader European platform. The strategy aims to double EBITDA to €300m and generate more than €3bn in revenue by 2031, marking the next step in Orifarm's journey as a diversified European pharmaceutical company bringing affordable medicines to more customers, patients and healthcare systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930257993/en/ Orifarm Headquarter, Odense Denmark “As European healthcare systems face rising demand, budget pressures, and supply challenges, Orifarm is uniquely positioned to improve access to affordable medicines and strengthen European supply. Our Fit to Scale strategy is about playing an even bigger role in meeting these needs and taking Orifarm to the next level,” says Mads Fink Eriksen,
Thales Launches Sentinel Envelope Plus to Protect Software Against AI-Assisted Reverse Engineering1.10.2026 08:01:00 CEST | Press release
Sentinel Envelope Plus, a new advanced software protection add-on, helps software vendors protect compiled applications against AI-assisted reverse engineering, automated vulnerability discovery, and exploit generation without requiring source code changes In a controlled test, an AI agent identified eight of 10 vulnerabilities in an unprotected application; once the application was protected with Sentinel Envelope Plus, it found none, and the analysis was halted after nearly seven hours. Thales, a global leader in advanced technologies, today announced Sentinel Envelope Plus, a new addition to its Sentinel Envelope software protection solution that significantly hardens compiled applications against AI-assisted reverse engineering, automated zero-day vulnerability discovery, and automated exploit generation. Sentinel Envelope Plus applies multiple layers of protection to software applications, without requiring source code changes or any special compilation environments. This press re
NHOA Energy Achieves UNI/PdR 125:2022 Gender Equality Certification1.10.2026 08:00:00 CEST | Press release
The certification marks another step in NHOA Energy’s commitment to equal opportunities and inclusive workplace NHOA Energy, global provider of utility-scale energy storage systems, has obtained the UNI/PdR 125:2022 Gender Equality Certification for its Gender Equality Management System in Italy. Issued by RINA following an independent audit, the certification evaluates the Company’s approach to gender equality through qualitative and quantitative indicators across six key areas: recruitment and hiring, career management, pay equity, parenting and caregiving, work-life balance, and the prevention of workplace abuse and harassment. “Building a strong company also means creating an environment where people have equal opportunities to contribute, grow and lead. This certification is an important recognition of the work already done, but above all a commitment to continue improving the way we support our People and strengthen our culture,” said Anita Maria Ganassali, VP Human Capital of NH
Thales Strengthens Data Security Posture Management to Address Emerging Risks of AI1.10.2026 08:00:00 CEST | Press release
Thales’ CipherTrust Data Security Posture Management platform brings together data discovery, risk analysis and integrated protection to help organizations move from identifying exposure to actively reducing data risk. It helps enterprises protect sensitive data as AI applications and autonomous agents gain access to information across increasingly complex environments. It connects prioritized data risks with protection capabilities across all environments; cloud, on-premises and hybrid environments. Thales, a global leader in advanced technologies for cybersecurity markets, today announced CipherTrust Data Security Posture Management (DSPM). It is the first purpose-built DSPM offering designed to help organizations go beyond discovering exposed sensitive data and applying access-based remediation, enabling them to prioritize risks and protect their most sensitive data directly through encryption, masking, or tokenization natively within the platform. This press release features multim
Tigo Energy Builds on 80MW of C&I Solar Growth in Czechia with GO Optimized ESS for Residential1.10.2026 06:00:00 CEST | Press release
Strong commercial solar market performance in Czechia and installer trust in solar hardware provide a foundation for Tigo GO Optimized ESS showcase at Smart Energy Forum 2026 in Prague. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company will showcase the Tigo GO Optimized Energy Storage Solution (ESS) at Smart Energy Forum (SEF) 2026 in Prague, building on strong adoption of Tigo technology across the Czech commercial and industrial (C&I) solar market. Since 2024, Czech installers have deployed Tigo products in approximately 80MW of C&I systems, providing a solid foundation for Tigo to expand its residential solar-plus-storage offering. Across residential, small commercial, and larger C&I applications, installers in Czechia have deployed approximately 276MW of Tigo systems since 2024. At the heart of the Tigo showcase will be the Tigo GO Optimized ESS, featuring the expanded sto
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom